Complete details on the stipends and an application can be found here: www.issm.info/grants1/travel-stipends-2016
Furthermore, ISSM will be providing 10 Scholarships to the ESSM School of Sexual Medicine taking place in Budapest, Hungary, October 2016.
Complete details on the Scholarships and an application can be found here: www.issm.info/grants1/issm-scholarships
Read more ...
2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia.
In 2015, the International Society for the Study of Vulvovaginal Disease (ISSVD), International Society for the Study of Women's Sexual Health (ISSWSH) , and International Pelvic Pain Society (IPPS) adopted a new vulvar pain and vulvodynia terminology that acknowledges the complexity of the clinical presentation and pathophysiology involved in vulvar pain and vulvodynia, and incorporates new information derived from evidence-based studies conducted since the last terminology published in 2003. The article “2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia.” has been published simultaneously in the Journal of Lower Genital Tract Diseases and Obstetrics & Gynecology and will be published soon in the Journal of Sexual Medicine.
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women A Systematic Review and Meta-Analysis, Loes Jaspers; Frederik Feys; Wichor M. Bramer; Oscar H. Franco; Peter Leusink; Ellen T. M. Laan; JAMA Intern Med. doi:10.1001/jamainternmed.2015.8565, Published online February 29, 2016.
and the accompanying editorial
US Food and Drug Administration Approval of Flibanserin, Even the Score Does Not Add Up, Steven Woloshin; Lisa M. Schwartz; JAMA Internal Medicine Published online February 29, 2016.
- Press Release
- Bullet Points Reference Article
- Bullet Points Accompanying Editorial
February 29, 2016 - Science has been corrupted by bias and personal agendas resulting in publication of a distorted analysis of outcomes of research trials. As authorities in the area of sexual function and dysfunction in women, in particular hypoactive sexual desire disorder (HSDD), the Board of Directors of the International Society for the Study of Women's Sexual Health (ISSWSH)1 is concerned that the aforementioned articles would be accepted by and published as quality science and factual commentary. According to Levine, the diverse controversies involving treatments for sexual difficulties have resulted in stakeholders interpreting science for us in ways that support their political ideological views, economic interests, or skill sets.2 This is clearly the case with regard to both the Jaspers et al. article and subsequent editorial response. We wish to set the record straight. When articles that reflect opinion rather than science are published in scientific journals, they harm those meant to be aided by science and medicine resulting, in this case, in a great disservice to the millions of pre-menopausal women suffering from HSDD.